MIRA
MIRA Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.76
+3.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$32.10M
MomentumView details →
1D Return
+3.27%
YTD Return
−49.54%
RSI (14)
47.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$32.10M
RSI (14)
47.1
MomentumView details →
1D Return
+3.27%
YTD Return
−49.54%
SummaryUpdated Jun 1, 2026
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Baltimore, Maryland. The company went public in August 2023 and focuses on developing novel synthetic cannabinoid therapies for neurological and psychiatric conditions. MIRA was formerly known as MIRA1a Therapeutics, Inc. before its corporate restructuring and public listing. As a pre-revenue biotech company, MIRA is currently in the clinical development phase with its lead drug candidate targeting anxiety and cognitive decline associated with early-stage dementia.
Similar companies
Latest newsMore news →
MIRA Pharmaceuticals announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs, advancing the non-opioid oral drug toward an IND filing.4d agoMIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of its obesity treatment candidate SKNY-1 in Beagle dogs, supporting advancement toward GLP toxicology studies and IND-enabling development.30d agoMIRA Pharmaceuticals announced positive preclinical results for an optimized oral formulation of MIRA-55, a non-opioid therapy for chronic inflammatory pain.57d ago